Previous Close | 0.2500 |
Open | 0.2550 |
Bid | 0.2550 x N/A |
Ask | 0.2700 x N/A |
Day's Range | 0.2550 - 0.2550 |
52 Week Range | 0.1950 - 0.6800 |
Volume | |
Avg. Volume | 31,672 |
Market Cap | 63.653M |
Beta (5Y Monthly) | 3.71 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0750 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - March 23, 2023) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative wellness products, announced today the successful results of a controlled efficacy test (the "Trial") regarding its vaginal derma product (the "Product").The results of the Trial demonstrate that Innocan's Product, which contains cannabinoids, phytoestrogens, h
Announces the launch of its licensing and commercialization strategy work with respect to cannabinoid ...
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - March 17, 2023) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is excited to announce the launch of its licensing and commercialization strategy work with respect to cannabinoid (CBD) therapy in the veterinary field.Innocan CEO, Iris Bincovich, s